{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:48:21Z","timestamp":1782719301386,"version":"3.54.5"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["24K19108"],"award-info":[{"award-number":["24K19108"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a life-threatening event with high mortality. While systemic corticosteroids are commonly used in clinical practice for AE-IPF despite the absence of randomised evidence, the optimal tapering strategy is uncertain. Early corticosteroid tapering reduces adverse events in other inflammatory diseases. However, the efficacy and safety of this approach in AE-IPF have not been established. This study aims to determine if an early corticosteroid tapering regimen is non-inferior to a conventional regimen for 90-day mortality in patients with AE-IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The RApid PrednIsolone Dose reduction for acute exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF) trial is a multicentre, parallel-group, open-label, randomised controlled non-inferiority trial conducted in Japan. A total of 70 patients (up to 130) hospitalised for AE-IPF will be randomly assigned in a 1:1 ratio to either an accelerated 6-week prednisolone tapering regimen (early tapering group) or a conventional 12-week tapering regimen (standard tapering group). The primary outcome is all-cause mortality at 90 days. The non-inferiority margin is set at a 10% risk difference. Key secondary outcomes include 28-day mortality, mortality due to respiratory causes, time to respiratory worsening or death, protocol adherence and the proportion of patients lost to follow-up. The trial incorporates two interim analyses for feasibility and sample size re-estimation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study will be conducted in compliance with the Declaration of Helsinki and Japanese ethical guidelines. The protocol was approved by the institutional review boards of all participating hospitals (lead approval: Saiseikai Kumamoto Hospital, #1367). Written informed consent will be obtained from all participants or their legally acceptable representatives. Findings will be disseminated through scientific conferences and publication in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials (jRCT1071250015).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003818","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:30:19Z","timestamp":1782718219000},"page":"e003818","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of RApid PrednIsolone Dose reduction for acute exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF Trial): a study protocol for a randomised controlled trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05674994","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05674994","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-7334","authenticated-orcid":false,"given":"Keisuke","family":"Anan","sequence":"first","affiliation":[{"name":"Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan"},{"name":"Clinical Research Management Section, Saiseikai Kumamoto Hospital, Kumamoto, Japan"},{"name":"Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan"},{"name":"Center for Postgraduate Clinical Training and Career Development, Nagoya University Hospital, Aichi, Japan"},{"name":"Center for Medical Education, Graduate School of Medicine, Nagoya University, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, Tokyo Medical University, Shinjuku-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ichikado","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tachikawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Tobino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Iizuka Hospital, Iizuka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Shirakawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Iizuka Hospital, Iizuka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"2026062900300734000_13.1.e003818.1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026062900300734000_13.1.e003818.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2026062900300734000_13.1.e003818.3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0050-2017","article-title":"Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis","volume":"26","author":"Kondoh","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2026062900300734000_13.1.e003818.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159709"},{"key":"2026062900300734000_13.1.e003818.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01760-2019"},{"key":"2026062900300734000_13.1.e003818.6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.resinv.2024.02.014","article-title":"Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition","volume":"62","author":"Bando","year":"2024","journal-title":"Respir Investig"},{"key":"2026062900300734000_13.1.e003818.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2026062900300734000_13.1.e003818.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.6615"},{"key":"2026062900300734000_13.1.e003818.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537"},{"key":"2026062900300734000_13.1.e003818.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-022-02195-3","article-title":"Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"23","author":"Anan","year":"2022","journal-title":"Respir Res"},{"key":"2026062900300734000_13.1.e003818.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081477","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"BMJ"},{"key":"2026062900300734000_13.1.e003818.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044480","article-title":"Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics","volume":"11","author":"Pong","year":"2021","journal-title":"BMJ Open"},{"key":"2026062900300734000_13.1.e003818.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.19.2588"},{"key":"2026062900300734000_13.1.e003818.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61879-1"},{"key":"2026062900300734000_13.1.e003818.15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/cer-2020-0200","article-title":"A systematic review of noninferiority margins in oncology clinical trials","volume":"10","author":"Hashim","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2026062900300734000_13.1.e003818.16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026062900300734000_13.1.e003818.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07882-0"},{"key":"2026062900300734000_13.1.e003818.18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40814-021-00770-x","article-title":"Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back!","volume":"7","author":"Lewis","year":"2021","journal-title":"Pilot Feasibility Stud"},{"key":"2026062900300734000_13.1.e003818.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i5239","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"key":"2026062900300734000_13.1.e003818.20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5691\/jjb.29.19","article-title":"A Modification of the 50%-Conditional Power Approach for Increasing the Sample Size Based on an Interim Estimate of Treatment Difference","volume":"29","author":"Uemura","year":"2008","journal-title":"JJB"},{"key":"2026062900300734000_13.1.e003818.21","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222636"},{"key":"2026062900300734000_13.1.e003818.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2031"},{"key":"2026062900300734000_13.1.e003818.23","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-41","article-title":"The statistical interpretation of pilot trials: should significance thresholds be reconsidered?","volume":"14","author":"Lee","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026062900300734000_13.1.e003818.24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/resp.14788","article-title":"Treatment of acute exacerbations of interstitial lung diseases with corticosteroids: Evidence?","volume":"29","author":"Hung","year":"2024","journal-title":"Respirology"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:30:22Z","timestamp":1782718222000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,28]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjresp-2025-003818"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003818","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}